Neuland Laboratories has announced the successful completion of its recent postal ballot, with shareholders approving two significant leadership re-designations. The e-voting process, which ran from October 7 to November 5, 2025, saw overwhelming support for the proposed changes in the company's top management.

Key Resolutions Passed

1. Re-designation of Mr. Davuluri Sucheth Rao: Shareholders approved the re-designation of Mr. Davuluri Sucheth Rao (DIN: 00108880) as Executive Vice Chairman.

2. Re-designation of Mr. Davuluri Saharsh Rao: The re-designation of Mr. Davuluri Saharsh Rao (DIN: 02753145) as Chief Executive Officer & Managing Director was also approved.

Voting Results

Both resolutions received near-unanimous support from shareholders across all categories. The detailed voting results are as follows:

Shareholder Participation

The e-voting saw significant participation from shareholders:

• Promoter and Promoter Group: 98.79% of their shares were voted, all in favor of both resolutions.
• Public Institutions: 70.94% of institutional shares were voted, with 100% support for both resolutions.
• Public Non-Institutions: While only 2.72% of shares in this category were voted, they showed overwhelming support with 99.99% voting in favor.

Scrutinizer's Report

The e-voting process was scrutinized by CS Shaik Razia, Partner at D. Hanumanta Raju & Co., Company Secretaries. The scrutinizer confirmed the validity of the voting process and the results.

Compliance and Disclosure

In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Neuland Laboratories has promptly disclosed the voting results to the stock exchanges. Ms. Sarada Bhamidipati, Company Secretary and Compliance Officer, has been entrusted with completing the necessary formalities related to this postal ballot.

These leadership changes, approved by an overwhelming majority of shareholders, signal a new chapter in Neuland Laboratories' corporate governance and management structure. The strong support from all categories of shareholders indicates confidence in the company's strategic decisions and future direction under the newly designated leadership roles.

Neuland Laboratories , a prominent player in the pharmaceutical API manufacturing sector, has scheduled its Q2 FY26 earnings announcement and conference call for November 7, 2025. This announcement comes as the company prepares to share its financial results for the quarter and half-year ended September 30, 2025.

Key Details of the Earnings Call

The company has confirmed that the financial results will be made available on their official website, www.neulandlabs.com , coinciding with the announcement.

Company Overview

Neuland Laboratories has established itself as a significant player in the pharmaceutical industry over the past four decades. Here are some notable achievements of the company:

• Operates cGMP manufacturing facilities
• Serves customers in nearly 80 countries
• Developed over 300 processes and 100 APIs
• Filed approximately 990+ regulatory filings globally
• Maintains 72 active US Drug Master Files (DMFs)

Regulatory Compliance and Certifications

Neuland Labs' commitment to quality and reliability is evident through its extensive list of certifications, including:

• U.S. FDA
• TGA (Australia)
• EDQM (EU)
• German Health Authority
• ANVISA (Brazil)
• EMA (EU)
• Cofepris (Mexico)
• KFDA (Korea)
• PMDA (Japan)
• CFDA (China)
• FSI "SID & GP" Russia
• Health Canada
• ISO 9001, ISO14001, OHSAS18001, and ISO 27001

This upcoming earnings call presents an opportunity for investors and analysts to gain insights into Neuland Laboratories' performance and future outlook. Interested parties can register for the call using the provided Diamond Pass link.

For those seeking more information about Neuland Laboratories or wishing to participate in the earnings call, the company has provided the following contact details:

• For general inquiries: ir@neulandlabs.com
• For specific queries: Ravi Udeshi at ravi.udeshi@in.ey.com

As the pharmaceutical industry continues to evolve, Neuland Laboratories' Q2 FY26 results may offer valuable insights into the company's position in the market and its strategies for growth in the coming quarters.